| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | parbendazole | CTRPv2 | pan-cancer | AAC | -0.06 | 0.05 |
| mRNA | Nilotinib | CCLE | pan-cancer | AAC | -0.097 | 0.05 |
| mRNA | KH-CB19 | CTRPv2 | pan-cancer | AAC | 0.089 | 0.05 |
| mRNA | BRD-K27188169:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.1 | 0.06 |
| mRNA | KIN001-236 | GDSC1000 | pan-cancer | AAC | -0.064 | 0.06 |
| mRNA | BIBR-1532 | CTRPv2 | pan-cancer | AAC | -0.07 | 0.06 |
| mRNA | ZM-447439 | GDSC1000 | pan-cancer | AAC | -0.069 | 0.06 |
| mRNA | RO-3306 | GDSC1000 | pan-cancer | AAC | 0.066 | 0.06 |
| mRNA | foretinib | GDSC1000 | pan-cancer | AAC | -0.061 | 0.06 |
| mRNA | PF-3758309 | CTRPv2 | pan-cancer | AAC | -0.082 | 0.06 |